Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Receivables (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Change in Receivables data on record, last reported at -$159977.0 in Q4 2025.

  • For Q4 2025, Change in Receivables fell 606.46% year-over-year to -$159977.0; the TTM value through Dec 2025 reached -$77178.0, up 30.03%, while the annual FY2025 figure was $114690.0, 24.07% up from the prior year.
  • Change in Receivables reached -$159977.0 in Q4 2025 per INM's latest filing, down from -$122160.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $207019.0 in Q4 2023 and bottomed at -$165188.0 in Q1 2024.
  • Average Change in Receivables over 5 years is $10230.4, with a median of $10198.0 recorded in 2021.
  • The widest YoY moves for Change in Receivables: up 14451.57% in 2022, down 2592.58% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$638.0 in 2021, then skyrocketed by 14451.57% to $91563.0 in 2022, then surged by 126.09% to $207019.0 in 2023, then tumbled by 110.94% to -$22645.0 in 2024, then plummeted by 606.46% to -$159977.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$159977.0 in Q4 2025, -$122160.0 in Q3 2025, and $99715.0 in Q2 2025.